12
Participants
Start Date
September 30, 2013
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
erlotinib hydrochloride
"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
quinacrine dihydrochloride - Escalation dose
Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
quinacrine dihydrochloride - Extension dose
Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer, Cleveland
Neelesh Sharma MD PhD
OTHER